Drug Developer Painpoint
Cellistic Solution

Speed to clinic

Long and unpredictable development timelines, 24months+.

Standardized iPSC-to-NK workflows enable predictable, accelerated timelines. No process or analytical development is required, only 7 months for process adaptation, the entire offering in 18 months.

Budget Predictability

Difficulty forecasting costs due to process variability.

Fixed pricing model for accurate and reliable cost forecasting.

Supply Security & Scalability

 Achieving sufficient yields for long-term supply security. 

Scalable, high-yield Echo™-NK process delivering consistent, off the shelf supply.

Regulatory

Advancing with confidence in a comparatively new regulatory environment.

Your NK drug product is produced in our purpose-built EMA-certified, FDA compliant facility.

Speed to clinic

Drug Developer Painpoint

Long and unpredictable development timelines, 24months+.

Cellistic Solution

Standardized iPSC-to-NK workflows enable predictable, accelerated timelines. No process or analytical development is required, only 7 months for process adaptation, the entire offering in 18 months.

Budget Predictability
Drug Developer Painpoint

Difficulty forecasting costs due to process variability.

Cellistic Solution

Fixed pricing model for accurate and reliable cost forecasting.

Supply Security & Scalability
Drug Developer Painpoint

 Achieving sufficient yields for long-term supply security. 

Cellistic Solution

Scalable, high-yield Echo™-NK process delivering consistent, off the shelf supply.

Regulatory
Drug Developer Painpoint

Advancing with confidence in a comparatively new regulatory environment.

Cellistic Solution

Your NK drug product is produced in our purpose-built EMA-certified, FDA compliant facility.

NK-cells-1


Discover what comes standard with the Echo™-NK offering

Key elements of our Core Offering — delivering 20+ billion cells in 18 months for €3 million — include:

  • End-to-end platform process — client provides their unique CAR construct(s)
  • Scalable iPSC-to-NK expansion (30×) with bioreactors up to 50–100 L, from early to commercial scale
  • Up to 200 doses per batch
  • Feeder-free process with fully defined, GMP-compliant materials
  • Robust, qualified vendor supply chain

Download the full Core Offering Overview to see everything that’s included.

Echo-NK Platform Overview & In-Process Controls

NK Platform Overview & In-Process Controls

A process built for quality and consistency in iPSC-NK manufacturing

Generating clinical-grade iPSC NK cells at consistent yields with Echo-NK  is made possible through a proven process built in unit operations (with multiple in-process controls) and through multiple cryopreservation steps. 

GMP Facility for iPSC-Derived Allogeneic Cell Therapies

Purpose-built to build better cell therapies

In Mont-Saint-Guibert, Belgium, you’ll find our headquarters – and the world’s first facility dedicated exclusively to iPSC-based cell therapy manufacturing. It’s an agile, flexible, 20,000+ sq. ft. facility that incorporates leading-edge technologies. All materials and operations are validated according with cGMP standards, and manufacturing is conducted in an EMA-certified, FDA compliant GMP facility.

5 Grade B Manufacturing Suites

Grade B
Manufacturing Suites

4 Grade C Manufacturing Suites

Grade C
Manufacturing Suites

GMP Manufacturing

Clean Rooms for
CLD/GMP Manufacturing

5 GTP Inspections

GTP Inspections

7 GMP Inspections

GMP Inspections

10+ Allogeneic Batches Released

Allogeneic Batches Released

Advantage icon
Plug-and-play platform

Save time through an 80% pre-developed framework and, where needed, product-specific customization.

Advantage icon
Reliable starting material

Ensure reproducibility, simplify IP management, and provide long-term supply security though renewable GMP iPSC banks and STAR-CRISPR™ editing.

Advantage icon
In-house QC/QA

Inform release criteria and comparability protocols through assays that test for identity, safety, and purity.

Advantage icon
Scalable, compliant manufacturing

Scale confidently – and in regulatory alignment –  through Pulse™ automation, 3D bioreactors, and processes that can yield up to 100L using the same technologies.

Advantage icon
Quick time-to-value

Speed trial starts and positively impact company valuation through access to clinic-ready material in 18 months (versus industry-standard 24-month timelines).

Advantage icon
Efficient processes

Capitalize on scalable production process founded on iPSC cell lines that eliminate the need of expensive component editing at a manufacturing scale (i.e., viral vectors/DNA/RNA).

Advantage icon
Optimized cost structure and scalability

Improve margins, market penetration, and long-term program sustainability by leveraging favorable per-dose COGS, scalable production, and a broader patient reach.

Advantage icon
Strategic advantage

Enhance competitiveness, investor confidence, and program longevity by adopting a model purpose-built to meet the needs of NK cell therapy innovators.

Scientific Advantages

Advantage icon
Plug-and-play platform

Save time through an 80% pre-developed framework and, where needed, product-specific customization.

Advantage icon
Reliable starting material

Ensure reproducibility, simplify IP management, and provide long-term supply security though renewable GMP iPSC banks and STAR-CRISPR™ editing.

Advantage icon
In-house QC/QA

Inform release criteria and comparability protocols through assays that test for identity, safety, and purity.

Advantage icon
Scalable, compliant manufacturing

Scale confidently – and in regulatory alignment –  through Pulse™ automation, 3D bioreactors, and processes that can yield up to 100L using the same technologies.

Commercial Advantages

Advantage icon
Quick time-to-value

Speed trial starts and positively impact company valuation through access to clinic-ready material in 18 months (versus industry-standard 24-month timelines).

Advantage icon
Efficient processes

Capitalize on scalable production process founded on iPSC cell lines that eliminate the need of expensive component editing at a manufacturing scale (i.e., viral vectors/DNA/RNA).

Advantage icon
Optimized cost structure and scalability

Improve margins, market penetration, and long-term program sustainability by leveraging favorable per-dose COGS, scalable production, and a broader patient reach.

Advantage icon
Strategic advantage

Enhance competitiveness, investor confidence, and program longevity by adopting a model purpose-built to meet the needs of NK cell therapy innovators.

FAQ

Echo-NK Paper Mockup

Discover what comes standard
with every Echo-NK package

Behind every Echo-NK package is a team of experts and a suite of capabilities that are primed to speed your NK program to clinic. Download our Package Overview for a more detailed look at the technologies, services, documentation, and testing that make Echo-NK so unique. 
CELL-25-011-Echo-page-graphics-blob-6

Learn more about what Echo-NK can do for you

If accelerating your NK program efficiently is a critical priority for your team, then you'll find our team at Cellistic to be an ideal partner. No matter your starting point, our expertise can help you  advance to clinic with speed, scalability, and cost efficiency.